Kreaxi
  • Home
  • Company
  • Funds
  • Team
  • Portfolio
  • News
  • Contact
  • Français
Select Page

Theranexus to present the results of THN102 for Parkinson’s disease at the 2020 International Congress of Parkinson’s Disease and Movement disorders

Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, will present the Phase II results of its drug candidate THN102...

Amoéba: the efficacy of the biocontrol solution against grapevine downy mildew confirmed through the second European field trials campaign

AMOEBA (FR0011051598 – AMEBA), – producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces that the results of the second field trials...

Field tests confirm the efficacy of Amoeba’s biocontrol solution on several major wheat diseases

AMOEBA (FR0011051598 – AMEBA) – producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces the first efficacy results of its biocontrol...

Recent Posts

  • Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
  • Theranexus, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/ private laboratory “NeuroImaging for Drug Discovery” (NI2D)
  • Amolyt Pharma announces research collaboration with PeptiDream
  • The Food and Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by Theranexus and BBDF
  • Presentation of the results of the phase IB Clinical study of THN201 for Alzheimer’s disease at the clinical trials on Alzheimer’s disease conference (CTAD)

Recent Comments

    Archives

    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • July 2020
    • April 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • July 2019
    • March 2019
    • February 2019
    • December 2018
    • November 2018
    • December 2017
    • September 2017
    • April 2017

    Categories

    • News portfolio

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About

    Kreaxi is an investment management firm specialized in the equity financing of innovative and tech startups with high growth potential. Kreaxi manages regional funds, active in Auvergne-Rhône-Alpes (80M€) as well as national funds (180M€).

    Lyon

    101, Chemin Vert
    69760 Limonest 
    France

    +33 4 72 52 39 39

    Paris

    13-15 rue Taitbout
    75009 Paris
    France

    +33 1 73 02 89 69

    • Twitter
    © 2019 Kreaxi. Tous droits réservés. Mentions légales. Informations réglementaires. Démarche ESG.